These results show that c-KIT inhibitors as CSC-targeting agents in combination with RH1 treatment might be used as an effective therapy to treat triple negative breast cancer while overcoming the development of RH1 resistance. This evidence concerns the gene KIT and triple-negative breast carcinoma.